Previous 10 | Next 10 |
Trevena (NASDAQ:TRVN) reported data from a study evaluating opioid drug Olinvyk (oliceridine) injection versus morphine for managing acute pain in elderly/overweight. The company said the study builds on the collaborative work with Albert Dahan and his research team at Leiden Univer...
OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a comparative study of respiratory physiology in younger subjects with OLINVYK and IV morph...
CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million...
CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recen...
Trevena, Inc. (TRVN) Q4 2021 Earnings Conference Call March 31, 2022 8:00 A.M. ET Company Participants Barry Shin - Senior Vice President and Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patricia Drake - Senior Vice President and Chief Commercial Officer Mark...
Trevena (TRVN +29.5%) stock rose March 31 following its Q4 results, which beat analysts' estimates. Q4 net loss attributable to common stockholders widened to -$14.7M, compared to -$11.9M in Q4 2020. For full year 2021, net loss attributable to common stockholders was -$52.3M, compared to -$2...
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a ...
Trevena press release (NASDAQ:TRVN): Q4 GAAP EPS of -$0.08 beats by $0.02. The Company today reported $66.9 million in cash and cash equivalents as of December 31, 2021, which it believes will be sufficient to fund operating expenses and capital expenditure requirements through the fourth qua...
-- OLINVYK ® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed new Chief Commercial Officer Topline data of OLINVYK vs IV morphine in high-risk subjects demonstrates statistically significant benefit in lowering ...
Trevena (NASDAQ:TRVN) is scheduled to announce Q4 earnings results on Thursday, March 31st, before market open. The consensus EPS Estimate is -$0.09 (-12.5% Y/Y) and the consensus Revenue Estimate is $0.46M (+557.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...